VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: Results of the NORTHERN trial

Molecular Therapy

Volumn 17, Issue 6, 2009, Pages 1109-1115

  Stewart, Duncan J ^a,b   Kutryk, Michael J B ^a   Fitchett, David ^a   Freeman, Michael ^a   Camack, Nancy ^a,b   Su, Yinghua ^b   Siega, Anthony Della ^c   Bilodeau, Luc ^d   Burton, Jeffrey R ^e   Proulx, Guy ^f   Radhakrishnan, Sam ^g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Victoria Heart Institute Foundation   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f LAVAL UNIVERSITY   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PLASMID DNA; VASCULOTROPIN;

ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC RETINOPATHY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; ELECTROCARDIOGRAPHY; FEMALE; GENE THERAPY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; HYPOTENSION; INFLAMMATION; ISCHEMIA; LEUKOCYTOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NEUROTOXICITY; PERICARDIAL DISEASE; PERIPHERAL EDEMA; RETINA DISEASE; RETINA HEMORRHAGE; REVASCULARIZATION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN TOXICITY; THORAX PAIN;

AGED; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; HUMANS; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67349287066     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.70     Document Type: Article

References (30)

1. Reilly, JP, Grise, MA, Fortuin, FD, Vale, PR, Schaer, GL, Lopez, J et al. (2005). Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J Interv Cardiol 18: 27-31.
2. Ferrara, N (1999). Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77: 527-543.
3. Asahara, T, Takahashi, T, Masuda, H, Kalka, C, Chen, D, Iwaguro, H et al. (1999). VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18: 3964-3972.
4. Losordo, DW, Vale, PR, Hendel, RC, Milliken, CE, Fortuin, FD, Cummings, N et al. (2002). Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105: 2012-2018.
5. Rosengart, TK, Lee, LY, Patel, SR, Kligfield, PD, Okin, PM, Hackett, NR et al. (1999). Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 230: 466-470.
6. Ferrara, N and Kerbel, RS (2005). Angiogenesis as a therapeutic target. Nature 438: 967-974.
7. Vincent, KA, Jiang, C, Boltje, I and Kelly, RA (2007). Gene therapy progress and prospects: Therapeutic angiogenesis for ischemic cardiovascular disease. Gene Ther 14: 781-789.
8. Henry, TD, Annex, BH, McKendall, GR, Azrin, MA, Lopez, JJ, Giordano, FJ et al. (2003). The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107: 1359-1365.
9. Simons, M, Annex, BH, Laham, RJ, Kleiman, N, Henry, T, Dauerman, H et al. (2002). Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial. Circulation 105: 788-793.
10. Filion, RJ and Popel, AS (2005). Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention. Am J Physiol Heart Circ Physiol 288: H263-H279.
11. Sato, K, Laham, RJ, Pearlman, JD, Novicki, D, Sellke, FW, Simons, M et al. (2000). Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thorac Surg 70 2113-2118.
12. Lazarous, DF, Shou, M, Stiber, JA, Dadhania, DM, Thirumurti, V, Hodge, E et al. (1997). Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 36: 78-85.
13. Henry, TD, Grines, CL, Watkins, MW, Dib, N, Barbeau, G, Moreadith, R et al. (2007). Effects of Ad5FGF-4 in patients with angina: An analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 50: 1038-1046.
14. Wright, MJ, Wightman, LM, Latchman, DS and Marber, MS (2001). In vivo myocardial gene transfer: Optimization and evaluation of intracoronary gene delivery in vivo. Gene Ther 8: 1833-1839.
15. Stewart, DJ, Hilton, JD, Arnold, JM, Gregoire, J, Rivard, A, Archer, SL et al. (2006). Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 13: 1503-1511.
16. Kastrup, J, Jorgensen, E, Ruck, A, Tagil, K, Glogar, D, Ruzyllo, W et al. (2005). Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: The Euroinject One trial. J Am Coll Cardiol 45: 982-988.
17. Grines, CL, Watkins, MW, Helmer, G, Penny, W, Brinker, J, Marmur, JD et al. (2002). Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105: 1291-1297.
18. Bush, MA, Samara, E, Whitehouse, MJ, Yoshizawa, C, Novicki, DL, Pike, M et al. (2001). Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. J Clin Pharmacol 41: 378-385.
19. Simons, M, Bonow, RO, Chronos, NA, Cohen, DJ, Giordano, FJ, Hammond, HK et al. (2000). Clinical trials in coronary angiogenesis: Issues, problems, consensus: An expert panel summary. Circulation 102 73-86.
20. Fam, NP, Verma, S, Kutryk, M and Stewart, DJ (2003). Clinician guide to angiogenesis. Circulation 108: 2613-2618.
21. Kapila, V, Sellke, FW, Suuronen, EJ, Mesana, TG and Ruel, M (2005). Nitric oxide and the angiogenic response: Can we improve the results of therapeutic angiogenesis? Expert Opin Investig Drugs 14: 37-44.
22. Heinl-Green, A, Radke, PW, Munkonge, FM, Frass, O, Zhu, J, Vincent, K et al. (2005). The efficacy of a 'master switch gene' HIF-1α in a porcine model of chronic myocardial ischaemia. Eur Heart J 26 1327-1332.
23. Yu, J, Lei, L, Liang, Y, Hinh, L, Hickey, RP, Huang, Y et al. (2006). An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice. FASEB J 20: 479-481.
24. Rana, JS, Mannam, A, Donnell-Fink, L, Gervino, EV, Sellke, FW and Laham, RJ (2005). Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol 95: 1456-1459.
25. Majesky, MW (1996). A little VEGF goes a long way. Therapeutic angiogenesis by direct injection of vascular endothelial growth factor-encoding plasmid DNA. Circulation 94: 3062-3064.
26. Wolff, JA (1997). Naked DNA transport and expression in mammalian cells. Neuromuscul Disord 7: 314-318.
27. Lekas, M, Kutryk, MJ, Latter, DA and Stewart, DJ (2004). Therapeutic neovascularization for ischemic heart disease. Can J Cardiol 20 (suppl. B): 49B-57B.
28. Celletti, FL, Hilfiker, PR, Ghafouri, P and Dake, MD (2001). Effect of human recombinant vascular endothelial growth factor165 on progression of atherosclerotic plaque. J Am Coll Cardiol 37: 2126-2130.
29. Moulton, KS, Heller, E, Konerding, MA, Flynn, E, Palinski, W and Folkman, J (1999). Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99: 1726-1732.
30. Kornowski, R, Hong, MK, Gepstein, L, Goldstein, S, Ellahham, S, Ben-Haim, SA et al. (1998). Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. Circulation 98 1116-1124.